Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Grifols SA (GRFe)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.03 -0.88    -9.90%
- Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Euro Zone
ISIN:  ES0171996087 
  • Volume: 12,854
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 8.00 - 8.46
Grifols 8.03 -0.88 -9.90%

Grifols SA Company Profile

 
Get an in-depth profile of Grifols SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

23631

Equity Type

ORD

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Contact Information

Address Avinguda de la Generalitat, 152 Parc de Negocis Can Sant Joan
Sant Cugat del Valles Barcelona, 08174
Spain
Phone 34 93 571 05 00
Fax 34 93 800 80 00

Top Executives

Name Age Since Title
Montserrat Muñoz Abellana 55 - Independent Director
Enriqueta Felip Font 59 2019 Independent Director
Thomas H. Glanzmann 65 2006 CEO & Executive Chairman
Darcy Antonellis 61 2023 Non-Executive Director
Juan Ignacio Twose Roura 78 1973 Member of the Advisory Committee
Tomas Daga Gelabert 68 2000 Independent External Director
Raimon Grifols Roura 60 2001 Vice-Chairman
Inigo Sánchez-Asiaín Mardones 60 2015 Independent Director
Carina Szpilka Lázaro 56 2015 Lead Independent Director
Víctor Grifols Deu 47 2016 Director
Albert Grifols Coma-Cros 45 2023 Executive Director
James Costos 61 2020 Independent Director
Nacho Abia 56 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GRLS Comments

Write your thoughts about Grifols SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Cristina Soro
Cristina Soro 14 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Socorro
Fernando Jimenez
Fernando Jimenez Mar 01, 2024 2:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vaya por Deu!
Emilio Cerezo
Emilio Cerezo Feb 12, 2024 4:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Daniu yyy
Daniu yyy Jan 29, 2024 5:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cuidado que son catalanes!!
El Inversor
El Inversor Jan 29, 2024 5:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Daniu yyy
Daniu yyy Jan 29, 2024 5:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
es broma
Javier del Valle Martin
Javier del Valle Martin Jan 09, 2024 7:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A Gowex sola la seguian ellos.. a Grifols mas de 20 analistas…. Ese es el dato
Jan 09, 2024 6:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Del informe por lo nenos hay una falacia, y es con respecto a la propiedad de los derechos de la primera de las citadas subsidiarias, su propiedad es del 100%; mas alla de eso todavia ne se sabe, pero ni todo es verdad ni todo es mentira.
Enrique Carmona Alcaide
Enrique Carmona Alcaide Jan 09, 2024 4:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Como corderos al matadero. El miedo se apodera de todo el accionariado y hoy se lucran los cortos. Abriendo palomitas…
Emilio Mari
Emilio Mari Mar 23, 2023 8:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
recuperaremos nuestro dinero o es una quiebra programada?
nelido valido
nelido valido Mar 10, 2023 4:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Volumen:528,569
Nov 11, 2022 1:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Viernes
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email